Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) …

Importance Novel sensitive methods for detection and monitoring of residual disease can
improve postoperative risk stratification with implications for patient selection for adjuvant …

Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …

Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with cancer.
However, existing biomarkers do not reliably predict treatment response across diverse …

PURPOSE Novel sensitive methods for early detection of relapse and for monitoring therapeutic
efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome …

Despite significant advances in early detection and treatment, breast cancer still remains a
major cause of morbidity and mortality for women. Our understanding of the molecular …

Purpose: Up to 30% of patients with breast cancer relapse after primary treatment. There
are no sensitive and reliable tests to monitor these patients and detect distant metastases …

OBJECTIVES: Autologous skeletal myoblast cell transplantation by means of the injection
method is subject to the loss of intercellular communication, extracellular matrix, and cell …

Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early
relapse detection may have a major impact on treatment decisions and patient management …

The SRC family kinases are the largest family of norreceptor tyrosine kinases and one of the
best-studied targets for cancer therapy. SRC, arguably the oldest oncogene, has been …